

Daiki TSUJI

52-1 Yada, Suruga-ku,
Shizuoka 422-8526 Japan
Phone: +81 54-264-5674
d-tsuji@u-shizuoka-ken.ac.jp

February 2017

Professional EXPERIENCES

- Apr. 2017 – present** Assistant Professor, Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka (Shizuoka Japan)
- Aug. 2009 – Mar. 2017** Research Assistant Professor, Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka (Shizuoka Japan)
- Oct. 2007 – Jul. 2009** Clinical Pharmacist, Department of Pharmacy, SEIREI Hamamatsu General Hospital (Hamamatsu Japan)
Position: Manager
- Apr. 2005 – Sep. 2007** Clinical Pharmacist, Department of Pharmacy, SEIREI Hamamatsu General Hospital (Hamamatsu Japan)
Position: Assistant Manager
- Apr. 2004 – Mar. 2005** Clinical Pharmacist, Division of Pharmacy, SEIREI Awagi Hospital (Awagi Japan)
- Apr. 2000 – Mar. 2004** Clinical Pharmacist, Department of Pharmacy, SEIREI Hamamatsu General Hospital (Hamamatsu Japan)

Portfolio URL: <http://w3pharm.u-shizuoka-ken.ac.jp/clinphar/>

BOARD CERTIFICATIONS

Board Certified Pharmacist in Oncology Pharmacy (BCPOP)
Board Certified Pharmacist, Japanese Society of Pharmaceutical Health Care and Sciences

PROFESSIONAL SOCIETY MEMBERSHIPS

- Japanese Society of Medical Oncology
- Japan Society of Clinical Oncology
- Japanese Society of Clinical Pharmacology
- Japanese Society of Pharmaceutical Oncology
- Japan Pharmacist Society of Disaster Relief
- Japanese Society of Pharmaceutical Health Care and Sciences
- Japanese Society of Hospital Pharmacists

ACADEMIC DEGREE

2015 Ph. D. Graduate School of Pharmaceutical Sciences, University of Shizuoka

EDUCATION

- 2000 M. Sc,** Department of Pharmacotherapy, Graduate School of Meiji Pharmaceutical University (Tokyo Japan)
- 1998 B. Sc,** Meiji Pharmaceutical University (Tokyo Japan)

PERSONAL INFORMATION

Name, Family name	TSUJI
Forenames	Daiki
Sex	Male
Date of Birth	28 Dec. 1974
Nationality	Japan

RESEARCH INTEREST

Oncology Pharmacotherapy and Supportive Care in Cancer

The overall objective and goal of my research work is to identify clinically relevant genetic polymorphisms in pharmacokinetic and pharmacodynamic pathways important for the treatment in solid tumor and in the field of supportive care. My long term goal is to introduce pharmacogenetic testing into the clinical setting to improve efficacy and safety of pharmacotherapy. To accomplish this, we are conducting a pharmacogenomics studies in clinical setting. We have collaborations with clinical investigators in oncology at SEIREI Hamamatsu General Hospital, Shizuoka General Hospital and Cancer Institute Hospital Japanese Foundation for Cancer Research.

RECENT PUBLICATIONS

- Tsuji D, Yokoi M, Suzuki K, Daimon T, Nakao M, Ayuhara H, Kogure Y, Shibata K, Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. *Pharmacogenomics J.* in press 2017
- Tsuji D, Ikeda M, Yamamoto K, Nakamori H, Kim YI, Kawasaki Y, Otake A, Yokoi M, Inoue K, Hirai K, Nakamichi H, Tokou U, Shiokawa M, Itoh K. Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study. *Medicine (Baltimore)*. **95**: e5151. (2016)
- Hirai K, Ishii H, Shimoshikiryo T, Shimomura T, Tsuji D, Inoue K, Kadoiri T, Itoh K. Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin. *Ther Drug Monit.* **38**: 706-710. (2016)
- Hirai K, Shimomura T, Moriwaki H, Ishii H, Shimoshikiryo T, Tsuji D, Inoue K, Kadoiri T,

- Itoh K. Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment. *Eur J Clin Pharmacol.* **72**: 1177-83. (2016)
- Inoue K, Murofushi T, Nagaoka K, Ando N, Hakamata Y, Suzuki A, Umemura A, Yoshida Y, Hirai K, Tsuji D, Itoh K. Influence of Genetic Polymorphisms and Concomitant Anxiolytic Doses on Antidepressant Maintenance Doses in Japanese Patients with Depression. *Biol Pharm Bull.* **39**: 1508-1513. (2016)
 - Todoroki K, Nakano T, Eda Y, Ohyama K, Hayashi H, Tsuji D, Min JZ, Inoue K, Iwamoto N, Kawakami A, Ueki Y, Itoh K, Toyo'oka T. Bioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification. *Anal Chim Acta.* **916**: 112-119. (2016)
 - Inoue K, Yamamoto Y, Suzuki E, Takahashi T, Umemura A, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K. Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. *Eur J Clin Pharmacol.* **72**: 555-562. (2016)
 - Inoue K, Takahashi T, Yamamoto Y, Suzuki E, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. *Seizure.* **33**: 76-80. (2015)
 - Tazoe Y, Hayashi H, Tsuboi S, Shioura T, Matsuyama T, Yamada H, Hirai K, Tsuji D, Inoue K, Sugiyama T, Itoh K. Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis. *Drug Metab Pharmacokinet.* **30**: 227-230. (2015)
 - Ikeda M, Tsuji D, Yamamoto K, Kim YI, Daimon T, Iwabe Y, Hatori M, Makuta R, Hayashi H, Inoue K, Nakamichi H, Shiokawa M, Itoh K. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. *Drug Metab Pharmacokinet.* **30**: 149-153. (2015)
 - Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, Inoue K, Itoh K. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. *Thromb Res.* **135**: 861-866. (2015)
 - Inoue K, Suzuki E, Takahashi T, Yamamoto Y, Yazawa R, Takahashi Y, Imai K, Miyakawa K, Inoue Y, Tsuji D, Hayashi H, Itoh K. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. *Epilepsy Res.* **108**: 1046-1051. (2014)
 - Saito M, Kondo M, Ohshima M, Deguchi K, Hayashi H, Inoue K, Tsuji D, Masuko T, Itoh K. Identification of anti-CD98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization. *Cancer Sci.* **105**: 396-401. (2014)
 - Tsuji D, Kamezato M, Daimon T, Taku K, Hatori M, Ikeda M, Hayashi H, Inoue K, Eto T, Itoh K. Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin. *Chemotherapy.* **59**: 407-413. (2013)

- Tsuji D, Kim YI, Nakamichi H, Daimon T, Suwa K, Iwabe Y, Hayashi H, Inoue K, Yoshida M, Itoh K. Association of ABCB1 Polymorphisms with the Antiemetic Efficacy of Granisetron plus Dexamethasone in Breast Cancer Patients. *Drug Metab Pharmacokinet.*, **28**, 299-304. (2013)
- Inoue K, Sonobe M, Kawamura Y, Etoh T, Takagi M, Matsumura T, Kikuyama M, Kimura M, Minami S, Utsuki H, Yamazaki T, Suzuki T, Tsuji D, Hayashi H, Itoh K. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. *Tohoku J Exp Med.*, **229**, 107-114. (2013)
- Hayashi H, Tazoe Y, Tsuboi S, Horino M, Morishita M, Arai T, Ohshima M, Matsuyama T, Kosuge K, Yamada H, Tsuji D, Inoue K, Itoh K. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. *Drug Metab Pharmacokinet.*, **28**, 164-168. (2013)
- Tsuji D, Kim YI, Taku K, Nakagaki S, Ikematsu Y, Tsubota H, Maeda M, Hashimoto N, Kimura M, Daimon T. Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial. *Support Care Cancer*, **20**, 1057-1064. (2012)
- Nakamichi H, Fujita T, Tsuji D, Atsumi I, Totsuka K, Suzuki R, Miki Y, Tomita K, Nakamura H, Shiokawa M. Analysis of risk factors of drug-induced lung injury in patients receiving gemcitabine treatment. *Gan To Kagaku Ryoho*, **39**, 787-792. (2012)
- Inoue K, Ando N, Suzuki E, Hayashi H, Tsuji D, Itoh K. Genotype distributions and allele frequencies of possible major depressive disorder-associated single nucleotide polymorphisms, cyclic adenosine monophosphate response element binding protein 1 rs4675690 and Piccolo rs2522833, in a Japanese population. *Biol Pharm Bull.*, **35**, 265-268. (2012)
- Hayashi H, Tazoe Y, Horino M, Fujimaki-Katoh C, Tsuboi S, Matsuyama T, Kosuge K, Yamada H, Tsuji D, Inoue K, Itoh K. An artifact derived from pseudogene led to the discovery of micro RNA binding site polymorphism in 3'-untranslated region of human dihydrofolate reductase gene. *Drug Metab. Pharmacokinet.*, **27**, 263-267. (2012)
- Hayashi H, Horino M, Morishita M, Tazoe Y, Tsuboi S, Matsuyama T, Kosuge K, Yamada H, Tsuji D, Inoue K, Itoh K. Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population. *Drug Metab. Pharmacokinet.*, **25**, 516-518. (2010)
- Ohshima M, Inoue K, Hayashi H, Tsuji D, Mizugaki M, Itoh K. Generation of AcGFP-labeled single-chain Fv against 5-methyl 2'-deoxycytidine from a hyperimmunized mouse using phage display technology. *Protein Eng. Des. Sel.*, **23**, 881-888. (2010)